Results 91 to 100 of about 779,609 (165)
Background: Biological therapy has revolutionized the treatment of inflammatory bowel disease (IBD). After the expiration of patents for biological innovator products, development of biosimilars increased. CT-P13 was the first biosimilar approved for the
Ágnes Milassin +2 more
doaj +1 more source
Biologiska läkemedel är effektiva vid flera sjukdomstillstånd men de är mycket dyra. År 2006 godkände den Europeiska läkemedelsmyndigheten försäljning av biosimilarer.
Adler, Anna
core +3 more sources
Yusuf Yazici,1 Lin Xie,2 Adesuwa Ogbomo,2 Lorie A Ellis,3 Kavitha Goyal,4 Amanda Teeple,5 Ismail Simsek6 1Rheumatology, New York University, School of Medicine, New York, NY, USA; 2Health Economics and Outcomes Research, STATinMED Research, Ann Arbor, MI,
Yazici Y +6 more
doaj
Soohyun Kim, 1, 2,* Siun Kim, 1, 2,* Howard Lee 1– 4 1Department of Transdisciplinary Studies, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea; 2Center for Convergence Approaches in Drug Development,
Kim S, Kim S, Lee H
doaj
Efficacy and safety of biosimilar IFX (CT-P13) and adalimumab in patients with active fistulizing perianal Crohn’s disease naďve to anti-TNF therapy: preliminary results from the POLIBD study [PDF]
Introduction. The development of perianal fistulas are a risk factor in colonic and rectal disease. Perianal CD treatment requires a combination of surgical and therapeutic treatments aimed to prevent septic complications, reduce fistula discharge and ...
Rafał Filip +7 more
core +2 more sources
Update on biosimilars in inflammatory bowel disease: Position and recommendations in Mexico
The biotechnology-derived medicines known as biosimilars are defined as non-originator treatments that have demonstrated quality, efficacy, and safety comparable to the reference biologic drug.
A. Mayoral-Zavala +9 more
doaj +1 more source
Resumen: Los medicamentos biotecnológicos biocomparables son definidos como tratamientos no innovadores que han demostrado calidad, eficacia y seguridad comparable al medicamento de referencia.
A. Mayoral-Zavala +9 more
doaj +1 more source
Background Biosimilars are biologic drugs that have the potential to increase the efficiency of healthcare spending and curb drug-related cost increases.
Marko Krstic +3 more
doaj +1 more source
Background and Aims: Infliximab, widely used as a mainstay treatment of inflammatory bowel disease (IBD), is traditionally administered intravenously. The subcutaneous (SC) formulation appears to offer a more convenient route of administration. This is a
Alejandro Nieto Dominguez +6 more
doaj +1 more source
Andrea Becciolini,1 Maria Gabriella Raimondo,2 Chiara Crotti,2 Elena Agape,2 Martina Biggioggero,2 Ennio Giulio Favalli1 1Department of Rheumatology, 2Department of Clinical Sciences and Health Community, University of Milan, Division of Rheumatology ...
Becciolini A +5 more
doaj

